Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17B | O94768 | 9/20 | 0.47 |
| ▸ | MAP3K8 | P41279 | 4/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | FLT1 | P17948 | 4/20 | 0.34 |
| ▸ | EGFR | P00533 | 3/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075052 | 0.90 | MAP3K8 (0.45) | STK17BMAP3K8IKBKBFLT1EGFR | |
| SCHEMBL4074723 | 0.90 | IKBKB (0.40) | STK17BMAP3K8IKBKBFLT1EGFR | |
| SCHEMBL4069660 | 0.90 | IKBKB (0.41) | STK17BMAP3K8IKBKBFLT1EGFR | |
| SCHEMBL4068216 | 0.87 | IKBKB (0.38) | STK17BMAP3K8IKBKBFLT1EGFR | |
| SCHEMBL3933687 | 0.87 | STK17B (0.44) | STK17BMAP3K8IKBKBFLT1EGFR | |
| SCHEMBL4066630 | 0.87 | MAP3K8 (0.41) | STK17BMAP3K8STK17AIKBKBFLT1 | |
| SCHEMBL4070004 | 0.87 | STK17B (0.37) | STK17BMAP3K8IKBKBFLT1EGFR | |
| SCHEMBL3930210 | 0.87 | HSD17B2 (0.41) | STK17BMAP3K8IKBKBFLT1EGFR | |
| SCHEMBL4071472 | 0.86 | IKBKB (0.35) | STK17BMAP3K8IKBKBFLT1EGFR | |
| SCHEMBL4076021 | 0.86 | STK17B (0.38) | STK17BMAP3K8IKBKBFLT1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | claimed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | claimed |
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | BAYER SHERING PHARMA AG (DE) | 2009-02-12 | — | — | US | disclosed |
| EP-2014663-A1 | Thieno-pyrimidyl amines as modulators of EP2 receptors | Bayer Schering Pharma AG (DE) | 2009-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042878-A1 | THIENOPYRIMIDYLAMINES AS MODULATORS OF THE EP2 RECEPTOR | PTGER2, PTGER1, PTGDR2 | STK17B 1911/4885MAP3K8 1493/4885STK17A 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.